Type 2 diabetes Trials in Jinan, China
Conditions / Type 2 diabetes / Jinan, China
Type 2 diabetes is a medical condition with active clinical research programs worldwide.
31 total trials for this combination
Showing top 10 of 31 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06448130 | Henagliflozin's Impact on Prediabetes Remission | NOT_YET_RECRUITING | PHASE4 |
| NCT06045221 | A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | COMPLETED | PHASE3 |
| NCT06269107 | A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) | COMPLETED | PHASE3 |
| NCT06109311 | A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor | COMPLETED | PHASE3 |
| NCT06323174 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise | COMPLETED | PHASE3 |
| NCT05872620 | A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes | COMPLETED | PHASE3 |
| NCT05971940 | A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone | COMPLETED | — |
| NCT06993792 | A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | ACTIVE_NOT_RECRUITING | — |
| NCT06972472 | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | RECRUITING | PHASE3 |
| NCT05362058 | A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time | COMPLETED | PHASE3 |